The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

If you’ve ever wondered what the inside of your body looks like, a local exhibit will give you a close-up look at the organs, bones, muscles, and more that make up ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

With the right sleep aids, you can dial in a better night’s sleep and boost your performance all from the comfort of your own ...

The retail sector is seeing strong momentum, fueled by consistent consumer spending and a positive outlook for sustained ...

University of Ferrara researchers in Italy have examined how European skin, eye and hair pigmentation evolved over the past ...

All of the OnePlus Watch 3's measurements come with the promise of enhanced accuracy compared to the Watch 2 by using a new ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Facialist Katie Sobelman, better known as The Organic Esthetician, combines clean beauty with advanced beauty technology for ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...